The Menopause Leadership Gap

Why Culturally Competent Care Is Now a Business and Economic Priority

A highly experienced woman walks into a meeting she has chaired dozens of times. She knows the figures. She understands the politics. She has spent years building the authourity to command the room.

Yet halfway through her presentation, the words disappear.

Her sleep has been fractured for months. Her concentration is unreliable. Her confidence is beginning to erode. She suspects stress, overwork or burnout. Her employer sees a performance problem. Her doctor may offer treatment for anxiety or depression before anyone asks a more fundamental question.

Could this be menopause?

For too many Black and South Asian women, that question is asked late. Sometimes it is never asked at all.

This is why menopause can no longer be treated solely as a private health matter. It is a leadership, workforce-retention and economic issue. When experienced women reduce their hours, step away from promotion, leave employment or scale back their businesses because symptoms are unrecognised or poorly managed, organisations do not simply lose an employee.

They lose expertise, relationships, institutional memory and future leadership.

The Cost of Treating Menopause as an Individual Problem

The UK workforce includes approximately 4.6 million women aged between 50 and 64.

There are now few organisations in which menopause is not being experienced by employees, managers, founders or senior decision-makers. Government reporting cites research indicating that one in ten women who worked during menopause left a job because of their symptoms. A further 13 per cent had considered leaving, while others reduced their hours or moved into part-time work.

The cost to employers has been estimated at approximately £1.5 billion a year through absence, reduced participation and women leaving work. These figures should concern every board, healthcare leader and policymaker.

Women in their forties, fifties and sixties are often operating at the point where experience, judgement and influence converge. They may be leading teams, managing risk, mentoring emerging talent, maintaining client relationships or running established businesses.

Losing them is not an unavoidable consequence of ageing. In many cases, it is a failure of recognition, medical access, workplace design and leadership.

For Black and South Asian women, the consequences may be compounded by health inequalities and workplace cultures in which they are already underrepresented at senior levels. A woman managing hot flushes, disrupted sleep, anxiety, joint pain or cognitive changes may also be managing racial bias, caregiving responsibilities, financial pressure and the expectation that she should continue performing without revealing vulnerability.

What looks like individual resilience may, in reality, be institutional neglect.

What HRT Can Offer

Hormone replacement therapy, commonly known as HRT, replaces some of the oestrogen, and sometimes progesterone, that the body produces in lower amounts during menopause.

HRT is the principal treatment recommended for menopausal hot flushes and night sweats. Evidence also supports its role in improving related sleep disturbance and quality of life, relieving vaginal symptoms and protecting bone density while treatment continues.

However, HRT should never be presented as a universal prescription or a universal danger.

The benefits and risks vary according to a woman’s age, symptoms, medical history, whether she has a uterus, the hormones used, the dose, the method of delivery and when treatment begins. NICE states that menopause care should be individualised and supported by shared decision-making using clear evidence about treatment choices.

Ethnicity alone does not determine whether HRT is safe. The clinically relevant questions concern the individual woman.

• Does she have uncontrolled hypertension, diabetes, migraine with aura, unexplained bleeding, liver disease or a history of blood clots?

• Does she smoke?

• Has she experienced breast cancer or another hormone-sensitive condition?

• What does her family history reveal?

• What medicines is she already taking?

These questions matter because population disparities must not be mistaken for biological destiny. Black women experience higher rates of some cardiovascular and metabolic conditions, but those risks are shaped by a complex interaction of healthcare access, socioeconomic inequality, chronic stress, environmental conditions and differential treatment within health systems.

The answer is not to deny HRT on the basis of ethnicity. It is to investigate properly, manage existing conditions and select treatment with greater precision.

The Difference the Delivery Method Can Make

Not all HRT carries the same risk profile.

Oral oestrogen passes through the liver and is associated with a higher risk of venous blood clots. Transdermal oestrogen, delivered through patches, gels or sprays, does not appear to increase that risk in the same way. NICE also advises that stroke risk is unlikely to increase with transdermal oestrogen, although oral oestrogen may increase risk depending on factors such as dose, age and duration of use.

This distinction can be particularly important for a woman with cardiovascular risk factors. It may mean that she requires a different formulation or specialist assessment rather than being told that HRT is simply unsuitable.

Women who still have a uterus will normally require progesterone alongside systemic oestrogen to protect the womb lining. Women who have had a total hysterectomy can often use oestrogen alone. The precise preparation should be decided through an informed clinical discussion rather than through social-media trends or generic prescribing.

The term “bioidentical” also requires care. Regulated body-identical hormones are licensed products with established standards of quality and dosage. Individually compounded bioidentical preparations may not have the same evidence, consistency or regulatory oversight. The word “natural” should never be treated as a substitute for safety evidence.

Vaginal oestrogen is another under-discussed treatment. It can relieve vaginal dryness, soreness, pain during sex and some bladder or urinary symptoms. These symptoms form part of genitourinary syndrome of menopause, a chronic condition that women may mistakenly accept as an inevitable part of ageing.

Women who cannot or do not wish to use HRT should also be offered evidence-based alternatives. These may include menopause-specific cognitive behavioural therapy, non-hormonal medicines, vaginal moisturisers, lubricants and support with sleep, physical activity, alcohol reduction and smoking cessation. NICE approved a new non-hormonal treatment option for moderate-to-severe hot flushes and night sweats in 2026 for some people for whom HRT is unsuitable.

Choice should mean genuine choice, not being pushed towards HRT without adequate assessment, but not being denied it because of outdated fears or poorly examined assumptions.

Why Black Women Are Still Entering the Conversation Late

A 2026 University College London study involving 377 Black women found that 88 per cent had received no menopause education at school, while 58 per cent felt completely uninformed before the age of 40. Many participants sought help only when symptoms had become severe and often turned first to friends or social media rather than formal health services.

Their experiences included misdiagnosis, being told they were too young, receiving antidepressants without a sufficient menopause assessment and encountering reluctance to discuss HRT.

This is not merely an information gap. It is a trust gap.

Professor Joyce Harper, who led the UCL research, has argued for better education and more inclusive menopause care. Adebukola 'Bukky' Ayoade, a NHS menopause lead and advocate for culturally responsive support, has similarly highlighted the need for healthcare that recognises how race, culture and lived experience affect whether women seek help and whether they feel heard.

Black clinicians and specialists including Dr Sherri-Ann Burnett-Bowie, Dr Monica Christmas and Dr Sharon Malone have also helped broaden public understanding of racial disparities in menopause experience and treatment. Their work challenges a medical model that historically treated the experiences of white women as universal.

Grassroots organisations have filled part of the gap left by formal institutions. Black Women in Menopause, Black Health and Beyond and community-led women’s networks have created spaces in which women can name symptoms, compare experiences and prepare for medical appointments without shame.

That contribution matters. Community advocacy should not replace qualified clinical care, but trusted grassroots voices can help women reach it sooner.

The Brain, Confidence and the Misdiagnosis of Leadership

Menopause is often reduced to hot flushes. For leaders, founders and professionals, some of the most disruptive symptoms may be cognitive and psychological.

Oestrogen interacts with brain systems involved in temperature regulation, sleep, mood, attention and memory. As hormone levels fluctuate, some women report difficulty retrieving words, sustaining concentration, processing information or managing emotional responses.

These changes do not mean that a woman has lost her intelligence or leadership capacity. However, persistent sleep disruption and anxiety can reduce working memory, increase cognitive load and make complex decision-making more difficult.

A senior woman who suddenly doubts her competence may withdraw from visible opportunities. A founder may mistake hormonal disruption for entrepreneurial burnout. A manager may avoid presentations because she fears forgetting her words. An employee may accept a lower-responsibility role rather than disclose what she is experiencing.

The organisation may record declining confidence. It may never record the conditions that produced it.

This is where culturally competent menopause care becomes economically significant. Effective support can preserve not only wellbeing, but participation, progression and leadership continuity.

What Employers Must Do Differently

A menopause policy is useful, but a policy sitting unnoticed on an intranet will not change experience. Government guidance published in 2026 reported that only 24 per cent of employees knew of a formal menopause policy in their workplace.

Senior leaders must move beyond awareness campaigns towards practical infrastructure.

Managers need the confidence to listen without diagnosing. Flexible working, temperature control, access to rest breaks, adjustments to uniforms, predictable scheduling and temporary changes to duties can make a substantial difference.

The quality of implementation must also be examined through a racial-equity lens.

• Do Black and South Asian women feel equally safe disclosing symptoms?

• Are they more likely to have their behaviour interpreted as difficult, emotional or disengaged?

• Are reasonable adjustments available to frontline and lower-paid workers as well as senior professionals?

• Are occupational-health pathways culturally informed?

The Equality and Human Rights Commission has made clear that severe menopause symptoms may, in some circumstances, meet the legal definition of disability and that employers may have duties to make reasonable adjustments and prevent discrimination.

Compliance should be the floor, not the ambition.

A mature organisation understands that menopause support is part of talent retention, succession planning, inclusion and responsible governance.

What Women Should Ask in the Consulting Room

A meaningful consultation should begin with the symptoms affecting your life, not with assumptions about what women of your ethnicity should tolerate.

Describe changes in sleep, menstrual patterns, mood, concentration, joint health, temperature regulation, vaginal comfort and urinary symptoms. Explain the effect on your work, relationships and daily functioning.

Ask:

• What treatment options are appropriate for your personal medical history.

• Whether a patch, gel or spray would offer advantages over tablets.

• Which form of progesterone is being recommended and why.

• Whether vaginal oestrogen could address local symptoms.

• What non-hormonal alternatives are available.

You should also understand when your treatment will be reviewed. NICE recommends reviewing HRT after it is started or changed and then regularly, commonly after three months and annually thereafter.

Menopause normally occurs between 45 and 55, although symptoms can begin several years earlier. Menopause before 45 is considered early, while menopause before 40 may indicate premature ovarian insufficiency and warrants timely clinical investigation.

Do not stop, start or alter HRT without discussing it with an appropriately qualified healthcare professional. This article provides education, not individual medical advice.

The Question Leaders Can No Longer Avoid

For years, the menopause conversation has focused on whether individual women should use HRT.

That remains an important clinical decision, but it is no longer the only question that matters. The larger question is whether healthcare systems and employers are equipped to prevent experienced women from disappearing from leadership at the very stage when their knowledge is most valuable.

When culturally competent care is missing, symptoms are more likely to be misunderstood, treatment may be delayed and women may be left to choose between their health and their visibility. This is not simply a women’s health failure. It is a failure of leadership, inclusion and economic judgement.

Black and South Asian women do not need assumptions made about their bodies. They need evidence, informed choice, appropriate investigation and healthcare professionals who listen before they prescribe or dismiss.

Employers do not need another commemorative menopause event without structural follow-through. They need managers who are trained, policies that are understood and working environments that retain women rather than quietly pushing them out.

The Paradigm Must Shift

Menopause is not the moment when women become less valuable to an organisation. It is the moment when organisations reveal how much they truly value women.

What has your experience of menopause support been. In the consulting room, the workplace or while running your own business? Did you receive informed choices or were you expected to cope in silence?

---

Like, comment and share this post. The woman questioning her capability may not need to step back. She may simply need the right information, the right care and a workplace ready to listen.

Join the conversation here